Cited by 431Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 148 of the 150 references it cites were found in a registry or an index.

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.

Lam, Raymond W., Kennedy, Sidney H., Grigoriadis, Sophie, McIntyre, Roger S., Milev, Roumen, Ramasubbu, Rajamannar, Parikh, Sagar V., Patten, Scott B., Ravindran, Arun V.·2009·Journal of Affective Disorders

DOI 10.1016/j.jad.2009.06.041

Open this paper in CoChat — free account

Abstract

Background In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. Methods The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included Levels of Evidence and expert clinical support. This section on "Pharmacotherapy" is one of 5 guideline articles. Results Despite emerging data on efficacy and tolerability differences amongst newer antidepressants, variability in patient response precludes identification of specific first choice medications for all patients. All second-generation antidepressants have Level 1 evidence to support efficacy and tolerability and most are considered first-line treatments for MDD. First-generation tricyclic and monoamine oxidase inhibitor antidepressants are not the focus of these guidelines but generally are considered second- or third-line treatments. For inadequate or incomplete response, there is Level 1 evidence for switching strategies and for add-on strategies including lithium and atypical antipsychotics. Limita…

Integrity signals

Registry

Crossref · 10.1016/j.jad.2009.06.041

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
The Serotonin Syndrome
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQUEEN, G. M., McIntyre, R. S., Sharma, V., et al. (2012) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,230
Self-citation
Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002

Show all 150 references

Research works printed but not linked: 1

Lam, 2004, Prescribing antidepressants for depression in 2005: recent concerns and recommendations, Can. J. Psychiatry, 49, 1

Sorted by citations

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citation
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Earlier studies that examined T3 augmentation of tricyclic antidepressants had mixed results (Lam et al., 2009), and systematic review of T3 augmentation of SSRIs (Cooper-Kazaz and Lerer, 2008) provides equivocal evidence for its efficacy.”
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials
Berlim, M. T., van den Eynde, F., Tovar-Perdomo, S., & Daskalakis, Z. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000512 · Cited by 620
Evidence-based clinical guidelines for immigrants and refugees
Pottie, K. C., Greenaway, C., Feightner, J., Welch, V. A., Swinkels, H. M., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 555
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 529
Self-citation
Depression in the Primary Care Setting
Park, L. T., & Zarate, C. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1712493 · Cited by 504
If at First You Donʼt Succeed
Connolly, K. R., & Thase, M. E. (2010) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 468
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
Self-citation
Treatment of Adult Depression in the United States
Olfson, M., Blanco, C., & Marcus, S. C. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.5057 · Cited by 352
Do guided internet-based interventions result in clinically relevant changes for patients with depression? An individual participant data meta-analysis
Karyotaki, E., Ebert, D. D., Donkin, L., Riper, H., Twisk, J., Burger, S., Rozental, A., Lange, A., Williams, A. D., Zarski, A. C., et al. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.007 · Cited by 303
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial
Lam, R. W., Levitt, A. J., Levitan, R. D., Michalak, E. E., Cheung, A. H., Morehouse, R., Ramasubbu, R., Yatham, L. N., & Tam, E. M. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2235 · Cited by 275
Self-citation
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Clinical Practice Guidelines for the management of Depression
Grover, S., Gautam, S., Jain, A., Gautam, M., & Vahia, V. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196973 · Cited by 269
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
(2018) · Europe PMC (PubMed Central) · Cited by 250
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
Shulman, K. I., Herrmann, N., & Walker, S. E. (2013) · CNS Drugs · doi:10.1007/s40263-013-0097-3 · Cited by 229
Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Staging methods for treatment resistant depression. A systematic review
Ruhé, H. G., van Rooijen, G., Spijker, J., Peeters, F. P. M. L., & Schene, A. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.020 · Cited by 210
Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders
Forte, A., Baldessarini, R. J., Tondo, L., Vázquez, G. H., Pompili, M., & Girardi, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.02.011 · Cited by 203
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis.
Linde, K., Sigterman, K., Kriston, L., Rucker, G., Jamil, S., Meissner, K., & Schneider, A. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1719 · Cited by 196
The suicide prevention effect of lithium: more than 20 years of evidence—a narrative review
Lewitzka, U., Severus, E., Bauer, R., Ritter, P. S., Müller-Oerlinghausen, B., & Bauer, M. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-015-0032-2 · Cited by 207
Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration
Ferreira Mello, B. S., Monte, A. S., McIntyre, R. S., Soczynska, J. K., Custódio, C. S., Cordeiro, R. C., Chaves, J. H., Mendes Vasconcelos, S. M., Nobre Júnior, H. V., Florenço de Sousa, F. C., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.008 · Cited by 195
Self-citation
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R. Z., Nomikos, G. G., Palo, W. A., & Reines, E. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628440 · Cited by 191
Does Lithium Prevent Alzheimerʼs Disease?
Forlenza, O. V., de Paula, V. D. J. R., Machado‐Vieira, R., Diniz, B. S., & Gattaz, W. F. (2012) · Drugs & Aging · doi:10.2165/11599180-000000000-00000 · Cited by 172
Depression in Primary Care: Current and Future Challenges
Craven, M. A., & Bland, R. C. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800802 · Cited by 168
Rates of Detection of Mood and Anxiety Disorders in Primary Care: A Descriptive, Cross-Sectional Study
Vermani, M., Marcus, M., & Katzman, M. A. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m01013 · Cited by 154
Momentary assessment technology as a tool to help patients with depression help themselves
Wichers, M., Simons, C. J. P., Kramer, I., Hartmann, J., Menne‐Lothmann, C., Myin‐Germeys, I., van Bemmel, A. L., Peeters, F. P. M. L., Delespaul, P., & van Os, J. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01749.x · Cited by 164
Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis
Linde, K., Kriston, L., Rücker, G., Jamil, S., Schumann, I., Meißner, K., Sigterman, K. E., & Schneider, A. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1687 · Cited by 160
Agomelatine in the Treatment of Major Depressive Disorder
Kennedy, S. H., & Rizvi, S. J. (2010) · CNS Drugs · doi:10.2165/11534420-000000000-00000 · Cited by 152
Self-citation
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
on behalf of the CAN-BIND Investigator Team, Lam, R. W. M., Milev, R. V., Rotzinger, S., Andreazza, A. C., Blier, P., Brenner, C. A., Daskalakis, Z. J., Dharsee, M., Downar, J. H., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0785-x · Cited by 152
Self-citation
Liothyronine for Depression: A Review and Guidance for Safety Monitoring.
Jaffer, K. Y., Chang, T., Vanle, B., Dang, J., Steiner, A. J., Loera, N., Abdelmesseh, M., Danovitch, I., & IsHak, W. W. (2017) · PubMed Central · Cited by 142
Treatment-Resistant Depression in Primary Care across Canada
Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., & Kennedy, S. H. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900702 · Cited by 144
Self-citation
European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings
Schosser, A., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., & Kasper, S. F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.006 · Cited by 136
Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study
Altamura, A. C., Buoli, M., Albano, A., & Dell’Osso, B. M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283384c74 · Cited by 137
Challenges in the Treatment of Major Depressive Disorder With Psychotic Features
Rothschild, A. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt046 · Cited by 133
Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults
MacQUEEN, G. M., Santaguida, P. L., Keshavarz, H., Jaworska, N., Levine, M., Beyene, J., & Raina, P. S. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716664885 · Cited by 130
Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review
Ravindran, A. V., & da Silva, T. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.042 · Cited by 121
Self-citation
The Efficacy and Safety of Low Frequency Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression: The Results From a Large Multicenter French RCT
Brunelin, J., Jalenques, I., Trojak, B., Attal, J., Székely, D. L., Gay, A., Januel, D., Haffen, É., Schott, A., Brault, C., et al. (2014) · Brain stimulation · doi:10.1016/j.brs.2014.07.040 · Cited by 127
A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
Self-citation
Prescription medication use by Canadians aged 6 to 79.
Rotermann, M., Sanmartin, C., Hennessy, D. A., & Arthur, M. (2014) · PubMed · Cited by 111
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.
Ravindran, A. V., Lam, R. W., Filteau, M. J., Lespérance, F., Kennedy, S. H., Parikh, S. V., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.040 · Cited by 108
Self-citation
Clinical effectiveness: The importance of psychosocial functioning outcomes
Lam, R. W. M., Filteau, M., & Milev, R. V. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.046 · Cited by 110
Self-citation
Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature
Dent, R., Blackmore, A., Peterson, J., Habib, R., Kay, G. P., Gervais, A., Taylor, V. H., & Wells, G. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036889 · Cited by 113
Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths
Ray, W. A., Stein, C. M., Murray, K. T., Fuchs, D. C., Patrick, S. W., Daugherty, J. R., Hall, K., & Cooper, W. O. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3421 · Cited by 101
Predictors of long-term prognosis of depression
Colman, I., Naicker, K., Zeng, Y., Ataullahjan, A., Senthilselvan, A., & Patten, S. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110676 · Cited by 110
Self-citation
Agomelatine versus other antidepressive agents for major depression
Guaiana, G., Gupta, S., Chiodo, D., Davies, S., Haederle, K., & Koesters, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008851.pub2 · Cited by 107
Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions
Kudlow, P. A., McIntyre, R. S., & Lam, R. W. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0171-5 · Cited by 99
Self-citation
Existing and Novel Biological Therapeutics in Suicide Prevention
Griffiths, J. J., Zarate, C. A., & Rasimas, J. J. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.06.012 · Cited by 97
Magnetic seizure therapy (MST) for major depressive disorder
Daskalakis, Z. J., Dimitrova, J., McClintock, S. M., Sun, Y., Voineskos, D., Rajji, T. K., Goldbloom, D. S., Wong, A. H. C., Knyahnytska, Y., Mulsant, B. H., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0515-4 · Cited by 92
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 92
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
Dodd, S., Bauer, M., Carvalho, A. F., Eyre, H. A., D, M. F. M., Kasper, S. F., Kennedy, S. H., Khoo, J., López‐Jaramillo, C., Malhi, G. S., et al. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1851052 · Cited by 100
Self-citation
Major depressive disorder: mechanism-based prescribing for personalized medicine
Lapolla, T., Saltiel, P. F., & Silvershein, D. I. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s73261 · Cited by 92
A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder
Lam, R. W. M., Michalak, E. E., & Yatham, L. N. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-78 · Cited by 90
Self-citation
Onset, time course and trajectories of improvement with antidepressants
Lam, R. W. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.005 · Cited by 86
Self-citation
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y. L., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 85
Self-citation
Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression
Dennis, C., & Dowswell, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006795.pub3 · Cited by 85
The Effects of Lithium on Renal Function in Older Adults—A Systematic Review
Rej, S., Herrmann, N., & Shulman, K. I. (2012) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988712436690 · Cited by 82
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Mindfulness meditation for workplace wellness: An evidence map
Hilton, L. G., Marshall, N. J., Motala, A., Taylor, S. L., Miake-Lye, I. M., Baxi, S. M., Shanman, R., Solloway, M. R., Beroesand, J. M., & Hempel, S. (2019) · Work · doi:10.3233/wor-192922 · Cited by 92
Multinational comparison of new antidepressant use in older adults: a cohort study
Tamblyn, R. M., Bates, D. W., Buckeridge, D. L., Dixon, W. G., Forster, A. J., Girard, N., Haas, J. S., Habib, B., Kurteva, S., Li, J., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027663 · Cited by 76
The hidden third: improving outcome in treatment-resistant depression
Schlaepfer, T. E., Ågren, H., Monteleone, P., Gastó, C., Pitchot, W., Rouillon, F., Nutt, D., & Kasper, S. F. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431748 · Cited by 76
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
(2019) · Europe PMC (PubMed Central) · Cited by 79
Neuropharmacological classification of antidepressant agents based on their mechanisms of action
Fasipe, O. (2018) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_7_18 · Cited by 80
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)
Kamijima, K., Higuchi, T., Ishigooka, J., Ohmori, T., Ozaki, N., Kanba, S., Kinoshita, T., & Koyama, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.07.035 · Cited by 74
Which Depressive Symptoms and Medication Side Effects Are Perceived by Patients as Interfering Most with Occupational Functioning?
Lam, R. W. M., Michalak, E. E., Bond, D. J., Tam, E. M., Axler, A., & Yatham, L. N. (2012) · Depression Research and Treatment · doi:10.1155/2012/630206 · Cited by 71
Self-citation
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 70
How Often Do Individuals with Major Depression Receive Minimally Adequate Treatment? A Population-Based, Data Linkage Study
Puyat, J. H., Kazanjian, A., Goldner, E. M., & Wong, H. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716640288 · Cited by 70
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
Dodd, S., Mitchell, P. B., Bauer, M., Yatham, L. N., Young, A. H., Kennedy, S. H., Williams, L. J., Suppes, T. M., López‐Jaramillo, C., Trivedi, M. H., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1379609 · Cited by 66
Self-citation
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials
Solmi, M., Veronese, N., Zaninotto, L., van der Loos, M. L. M., Gao, K., Schaffer, A., Reis, C., Normann, C., Anghelescu, I., & Correll, C. U. (2016) · CNS Spectrums · doi:10.1017/s1092852916000523 · Cited by 67
Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice
Fiorillo, A., Dell’Osso, B. M., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Vecchio, V. D., Nicola, M. D., Ferrari, S., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s83130 · Cited by 69
Agomelatine versus other antidepressive agents for major depression
Guaiana, G., Gupta, S., Chiodo, D., & Davies, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008851 · Cited by 68
A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study
Town, J. M., Abbass, A. A., Stride, C., & Bernier, D. C. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.035 · Cited by 81
Application of transcranial magnetic stimulation for major depression: Coil design and neuroanatomical variability considerations
Zibman, S., Pell, G. S., Barnea‐Ygael, N., Roth, Y., & Zangen, A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.06.009 · Cited by 65
Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration
Milea, D., Guelfucci, F., Bent‐Ennakhil, N., Toumi, M., & Auray, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.11.011 · Cited by 64
Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients
Henssler, J. F., Bschor, T., & Baethge, C. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743715620411 · Cited by 66
Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995
Murphy, Y., Wilson, E., Goldner, E. M., & Fischer, B. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0397-8 · Cited by 63
A comprehensive model of predictors of persistence and recurrence in adults with major depression: Results from a national 3-year prospective study
Hoertel, N., Blanco, C., Oquendo, M. A., Wall, M. M., Olfson, M., Falissard, B., Franco, S., Peyre, H., Lemogne, C., & Limosin, F. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.022 · Cited by 68
Treatment of the Depressed Alcoholic Patient
DeVido, J. J., & Weiss, R. D. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0314-7 · Cited by 66
Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report
Nogovitsyn, N., Muller, M., de Souza, R. M., Hassel, S., Arnott, S. R., Davis, A. D., Hall, G. B., Harris, J. K., Zamyadi, M., Metzak, P. D., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0542-1 · Cited by 66
Self-citation
The treatment of psychotic depression: Is there consensus among guidelines and psychiatrists?
Leadholm, A., Rothschild, A. J., Nolen, W. A., Bech, P., Munk‐Jørgensen, P., & Østergaard, S. D. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.036 · Cited by 61
Pharmacological prevention of suicide in patients with major mood disorders
Rihmer, Z., & Gonda, X. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.009 · Cited by 60
Neuromodulation for treatment-refractory major depressive disorder
Lipsman, N., Sankar, T., Downar, J. H., Kennedy, S. H., Lozano, A. M., & Giacobbe, P. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121317 · Cited by 65
Self-citation
Drug–drug interactions involving antidepressants: focus on desvenlafaxine
Low, Y. M., Setia, S., & Lima, G. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157708 · Cited by 63
Management of Treatment-Resistant Depression
Keitner, G. I., & Mansfield, A. K. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.004 · Cited by 62
Systematic review of management for treatment-resistant depression in adolescents
Zhou, X., Michael, K. D., Liu, Y., Giovane, C. D., Qin, B., Cohen, D., Gentile, S., & Xie, P. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0340-6 · Cited by 58
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: A randomized controlled trial
Costi, S., Soleimani, L., Glasgow, A., Brallier, J., Spivack, J., Schwartz, J., Levitch, C. F., Richards, S., Hoch, M., Stade, E. C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0365-0 · Cited by 56
The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature
Costemale-Lacoste, J.-F., Guilloux, J., & Gaillard, R. (2016) · L Encéphale · doi:10.1016/j.encep.2016.02.003 · Cited by 57
Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion
Vila‐Rodriguez, F., Dobek, C. E., Blumberger, D. M., Downar, J. H., & Daskalakis, Z. J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91126 · Cited by 56
The Mistreatment of Major Depressive Disorder
Paris, J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900306 · Cited by 53
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder
Blier, P., & Blondeau, C. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70003-9 · Cited by 58
A subject-independent pattern-based Brain-Computer Interface
Ray, A. M., Sitaram, R., Rana, M., Pasqualotto, E., Buyukturkoglu, K., Guan, C., Ang, K. K., Cristián Tejos, N., Zamorano, F. J., Aboitiz, F., et al. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00269 · Cited by 55
Serotonergic antidepressant use and morbidity and mortality among older adults with COPD
Vozoris, N. T., Wang, X., Austin, P. C., Stephenson, A. L., O’Donnell, D. E., Gershon, A. S., Gill, S. S., & Rochon, P. A. (2018) · European Respiratory Journal · doi:10.1183/13993003.00475-2018 · Cited by 54
Postpartum Depression: Diagnostic and Treatment Issues
Sharma, V., & Sharma, P. (2012) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)35240-9 · Cited by 57
Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder
Patkar, A. A., & Pae, C. (2013) · CNS Drugs · doi:10.1007/s40263-012-0031-0 · Cited by 50
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
Self-citation
Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial
Tadić, A., Wachtlin, D., Berger, T., Braus, D. F., van Calker, D., Dahmen, N., Dreimüller, N., Engel, A., Gorbulev, S., Helmreich, I., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.003 · Cited by 50
The History and Future of Ablative Neurosurgery for Major Depressive Disorder
Volpini, M., Giacobbe, P., Cosgrove, G. R., LEVITT, A. J., Lozano, A. M., & Lipsman, N. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000478025 · Cited by 49

Authors: Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V.
Affiliations: University of British Columbia (CA)
University of Toronto (CA)
Queen's University (CA)
University of Calgary (CA)
Corresponding author: Lam, Raymond W.
ORCID: Lam, Raymond W.
Kennedy, Sidney H.
Grigoriadis, Sophie
McIntyre, Roger S.
Milev, Roumen
Ramasubbu, Rajamannar
Parikh, Sagar V.
Patten, Scott B.
Ravindran, Arun V.
Venue: Journal of Affective Disorders
Publisher: Elsevier BV
Published: 2009-10
Volume: 117
Pages: S26-S43
ISSN: 0165-0327 (ISSN-L)
DOI: 10.1016/j.jad.2009.06.041
OpenAlex: W38793130
Cited by: 431
References: 150
Citations by year: 2026: 6 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 24 · 2017: 27 · 2016: 41 · 2015: 55 · 2014: 43 · 2013: 49 · 2012: 55
FWCI: 24.76
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Affective Disorders (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Network for Mood and Anxiety Treatments
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: major depressive disorder, antidepressant treatment, second-generation antidepressants, first-line therapy, inadequate response, switching strategy, adjunctive therapy, lithium, atypical antipsychotics, tricyclic antidepressants, monoamine oxidase inhibitors, treatment-resistant depression, adults
MeSH terms: Suicide Prevention, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Interactions, Humans, Sexual Dysfunction, Physiological, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks